Drugs / AZD1480
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01219543 | Nov 2010 → Dec 2012 | gastric cancer, hepatocellular carcinoma, metastatic carcinoma | AstraZeneca | Terminated | No outcome recorded |
| Phase 1 | NCT01112397 | Apr 2010 → Sep 2012 | cancer | AstraZeneca | Terminated | No outcome recorded |
| Phase 1 | NCT00910728 | May 2009 → Mar 2012 | acquired polycythemia vera, essential thrombocythemia, primary myelofibrosis | AstraZeneca | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2016-04-14 | AstraZeneca | Results AstraZeneca showcases breadth of Oncology portfolio at AACR 2016 Annual Meeting astrazeneca.com ↗
The Jak1/2 inhibitor AZD1480 suppresses tumor growth and metastasis in genetically engineered mouse models of PTEN-deficient prostate cancer |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2016-04-14 | AstraZeneca | AstraZeneca showcases breadth of Oncology portfolio at AACR 2016 Annual Meeting astrazeneca.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD1480 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00910728 ↗ |
| Action | Inhibit | “JAK2 inhibitor AZD1480” NCT00910728 ↗ |
| Modality | Small molecule | — CHEMBL1231124 ↗ |
| Route | Oral | “Oral capsule 2.5 mg, 10 mg and 40 mg” NCT00910728 ↗ |
| Target | JAK2 | “JAK2 inhibitor AZD1480” NCT00910728 ↗ |